.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 6,726,918

« Back to Dashboard

Claims for Patent: 6,726,918

Title: Methods for treating inflammation-mediated conditions of the eye
Abstract:Methods for treating inflammation-mediated conditions of the eye are described, comprising: implanting into the vitreous of the eye of an individual a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.
Inventor(s): Wong; Vernon G. (Menlo Park, CA), Hu; Mae W. L. (Los Altos Hills, CA)
Assignee: Oculex Pharmaceuticals, Inc. (Sunnyvale, CA)
Application Number:09/693,008
Patent Claims: 1. A method for treating an inflammation-mediated condition of the eye in an individual, comprising: implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.

2. The method according to claim 1, wherein the steroidal anti-inflammatory agent is selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone.

3. The method according to claim 1, wherein the steroidal anti-inflammatory agent is dexamethasone.

4. The method according to claim 1, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.1 .mu.g/ml dexamethasone within about 48 hours and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.

5. The method according to claim 1, wherein said concentration is maintained for least about four weeks.

6. The method according to claim 1, wherein the steroidal anti-inflammatory agent comprises about 50 to about 80 weight percent of the implant.

7. The method according to claim 6, wherein the steroidal anti-inflammatory agent comprises about 70% by weight of the implant.

8. The method according to claim 1, wherein the bioerodible polymer is a polyester.

9. The method according to claim 8, wherein the bioerodible polymer is polylactic acid polyglycolic acid (PLGA) copolymer.

10. The method according to claim 1, wherein the inflammation-mediated condition of the eye is selected from the group consisting of uveitis, macular edema, acute macular degeneration, retinal detachment, ocular tumors, fungal infections, viral infections, multifocal choroiditis, diabetic uveitis, proliferative vitreoretinopathy (PVR), sympathetic opthalmia, Vogt Koyanagi-Harada (VKH) syndrome, histoplasmosis, and uveal diffusion.

11. The method according to claim 10, wherein the inflammation-mediated condition of the eye is uveitis.

12. The method according to claim 10, wherein the inflammation-mediated condition of the eye is proliferative vitreoretinopathy (PVR).

13. The method according to claim 1, wherein the individual is a human.

14. A method for treating an inflammation-mediated condition of the eye in an individual, comprising: implanting a solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.05 .mu.g/ml dexamethasone within about 48 hours, and maintains a concentration equivalent to at least about 0.03 .mu.g/ml dexamethasone for at least about three weeks.

15. A method for treating an inflammation-mediated condition of the eye in an individual, comprising: implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.2 .mu.g/ml dexamethasone within about 6 hours and maintains a concentration equivalent to at least about 0.01 .mu.g/ml dexamethasone for at least about three weeks.

16. The method according to claim 15, wherein the steroidal anti-inflammatory agent is selected from the group consisting of cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone.

17. The method according to claim 15, wherein the steroidal anti-inflammatory agent is dexamethasone.

18. The method according to claim 15, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.4 .mu.g/ml dexamethasone within about 6 hours and maintains a concentration equivalent to at least about 0.01 .mu.g/ml dexamethasone for at least about three weeks.

19. The method according to claim 15, wherein the implant delivers the agent to the vitreous in an amount sufficient to reach a concentration equivalent to at least about 0.2 .mu.g/ml dexamethasone within about 6 hours and maintains a concentration equivalent to at least about 0.1 .mu.g/ml dexamethasone for at least about three weeks.

20. The method according to claim 15, wherein said concentration is maintained for least about four weeks.

21. The method according to claim 15, wherein said concentration is maintained for least about six weeks.

22. The method according to claim 15, wherein the steroidal anti-inflammatory agent comprises about 50 to about 80 weight percent of the implant.

23. The method according to claim 22, wherein the steroidal anti-inflammatory agent comprises about 70% by weight of the implant.

24. The method according to claim 22, wherein the steroidal anti-inflammatory agent comprises about 50% by weight of the implant.

25. The method according to claim 15, wherein the bioerodible polymer is a polyester.

26. The method according to claim 25, wherein the bioerodible polymer is polylactic acid polyglycolic acid (PLGA) copolymer.

27. The method according to claim 15, wherein the inflammation-mediated condition of the eye is selected from the group consisting of uveitis, macular edema, acute macular degeneration, retinal detachment, ocular tumors, fungal infections, viral infections, multifocal choroiditis, diabetic uveitis, proliferative vitreoretinopathy (PVR), sympathetic opthalmia, Vogt Koyanagi-Harada (VKH) syndrome, histoplasmosis, and uveal diffusion.

28. The method according to claim 27, wherein the inflammation-mediated condition of the eye is uveitis.

29. The method according to claim 27, wherein the inflammation-mediated condition of the eye is proliferative vitreoretinopathy (PVR).

30. The method according to claim 15, wherein the individual is a human.

31. A method for treating an inflammation-mediated condition of the eye in an individual, comprising: implanting a bioerodible solid body into the vitreous of the eye, said body comprising particles of a steroidal anti-inflammatory agent entrapped within a bioerodible polymer, whereby said agent is delivered to the vitreous at a rate and for a time sufficient to reach a concentration equivalent to at least about 0.2 .mu.g/ml dexamethasone within about 6 hours, and maintains a concentration equivalent to at least about 0.01 .mu.g/ml dexamethasone for at least about three weeks.

32. A solid bioerodible implant for treating an inflammation-mediated condition of the eye, consisting essentially of: dexamethasone particles entrapped within a polylactic acid polyglycolic acid (PLGA) copolymer, wherein the dexamethasone makes up between about 50 percent by weight and about 80 percent by weight of the implant, and wherein the implant releases at least about 10% of the drug load within 1 week when measured under infinite sink conditions in vitro.

33. A solid bioerodible implant for treating an inflammation-mediated condition of the eye, the implant consisting essentially of: dexamethasone particles entrapped within a polyactic acid polyglycolic acid (PLGA) copolymer matrix, wherein the dexamethasone makes up between about 50 percent by weight and about 80 percent by weight of the implant, and wherein the implant releases at least about 15% of the dexamethasone within 2 weeks when measured under infinite sink conditions in vitro.

34. The solid bioerodible implant of claim 33, wherein the implant releases at least about 20% of the dexamethasone within 2 weeks when measured under infinite sink conditions in vitro.

35. The solid bioerodible implant of claim 34, wherein the implant releases at least about 40% of the dexamethasone within 2 weeks when measured under infinite sink conditions in vitro.

36. A method for treating an inflammation-mediated condition of the eye in an individual, comprising: implanting into the vitreous of the eye a bioerodible implant comprising a steroidal anti-inflammatory agent and a bioerodible polymer, wherein the implant releases at least about 15% of the steroidal anti-inflammatory agent within 2 weeks when measured under infinite sink conditions in vitro.

37. The method according to claim 36, wherein the implant releases at least about 20% of the steroidal anti-inflammatory agent within 2 weeks when measured under infinite sink conditions in vitro.

38. The method according to claim 37, wherein the implant releases at least about 40% of the steroidal anti-inflammatory agent within 2 weeks when measured under infinite sink conditions in vitro.

39. The method according to claim 10, wherein the inflammation-mediated condition of the eye is macular edema.

40. The method according to claim 27, wherein the inflammation-mediated condition of the eye is macular edema.

41. The method according to claim 1, wherein the steroidal anti-inflammatory agent is fluocinolone acetonide.

42. The method according to claim 15, wherein the steroidal anti-inflammatory agent is fluocinolone acetonide.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc